NCT01450488View on ClinicalTrials.gov

Masitinib in Primary Progressive Multiple Sclerosis or Relapse-free Secondary Progressive Multiple Sclerosis

PHASE2CompletedINTERVENTIONAL

Enrollment

35

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

July 31, 2007

Study Completion Date

January 31, 2010

Conditions

Multiple Sclerosis

Interventions

DRUG

masitinib

masitinib 3 mg/kg/day

DRUG

masitinib

masitinib 6 mg/kg/day

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AB Science

INDUSTRY